Resources for you and your patients

THERA patient support® Program Resources

Patient Enrollment Form

Enroll your patients into the THERA patient support® Program.

EGRIFTA SV® THERA patient support® Patient Brochure

Provide patients with information about the THERA patient support® Program benefits and services.

EGRIFTA SV® THERA patient support® HCP Leave Behind

Learn more about the THERA patient support® Program benefits and services that are offered to you and your patients.

EGRIFTA SV® HCP & Patient Resources

Prescribing Information

View the complete product information for EGRIFTA SV®.

EGRIFTA SV® HCP Leave Behind

Learn about the key data, dosing and administration, and benefits of EGRIFTA SV® for you and your patients.

Doctor Discussion Guide

Provide patients with information about excess visceral abdominal fat and treatment with EGRIFTA SV®.

Step-by-step Administration Guide

Help your patients with any questions about mixing and injecting EGRIFTA SV®.

IMPORTANT SAFETY INFORMATION (Please see below for full limitations of use and additional important safety information)


EGRIFTA SV® is indicated for the reduction of excess abdominal fat in HIV‑infected adult patients with lipodystrophy.

Limitations of Use:

  • The impact and safety of EGRIFTA SV® on cardiovascular health have not been studied.
  • EGRIFTA SV® is not indicated for weight loss management.
  • It is not known whether taking EGRIFTA SV® helps improve compliance with anti‑retroviral medications.


Do not use EGRIFTA SV® if patient:

  • Has a pituitary gland tumor, has had pituitary gland surgery, has other problems related to their pituitary gland, or has had radiation treatment to their head or a head injury.
  • Has active cancer.
  • Is allergic to tesamorelin or any of the ingredients in EGRIFTA SV®.
  • Is pregnant or planning to become pregnant.

Warnings and Precautions

Drug Interactions

Use in Specific Populations

Adverse Reactions

The most commonly reported adverse reactions include injection site reactions, arthralgia, pain in extremity, myalgia, and peripheral edema.

To report suspected adverse reactions, contact THERA patient support® at 1‑833‑23THERA (1‑833‑238-4372) or FDA at 1‑800‑FDA-1088 or

Please see full Prescribing Information for EGRIFTA SV®.